KPIs & Operating Metrics(New)
Breakdown Of AssetsContractual Commitments And ObligationsCost Of SalesDevelopment ExpensesEffective Tax Rate %Employees By RegionGross Margin %Gross ProfitIncome Before Income Taxes By RegionInventory BreakdownLong Lived Assets By RegionNon Gaap ProfitabilityNon Gaap Profitability %Non Gaap Profitability AnnualNon Gaap Profitability Annual %Opex As A % Of Total Revenue %OPEX BreakdownProduct Revenue By RegionProduct Revenue By Region %Product Revenue By Region AnnualProduct Revenue By Region Annual %Property And Equipment BreakdownResearch Expenses BreakdownRevenue By Business VerticalRevenue By Business Vertical (Annual)Revenue By Business Vertical AnnualRevenue By Customer (Annual) %Revenue By Location Of Customer (Product)Revenue By Location Of Customer (Product) %Revenue By Location Of Customer (Product Annual)Revenue By Product CategoryRevenue By Product Category %Revenue By Product Category (Annual)Revenue Mix By Business Vertical Annual %Revenue Mix By Product Category (Annual) %
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Gross Profit (2016 - 2025)

Historic Gross Profit for Vertex Pharmaceuticals (VRTX) over the last 16 years, with Q4 2025 value amounting to $2.7 billion.

  • Vertex Pharmaceuticals' Gross Profit rose 945.91% to $2.7 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $10.4 billion, marking a year-over-year increase of 906.68%. This contributed to the annual value of $10.4 billion for FY2025, which is 906.68% up from last year.
  • According to the latest figures from Q4 2025, Vertex Pharmaceuticals' Gross Profit is $2.7 billion, which was up 945.91% from $2.7 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Gross Profit peaked at $2.7 billion during Q4 2025, and registered a low of $1.5 billion during Q1 2021.
  • For the 5-year period, Vertex Pharmaceuticals' Gross Profit averaged around $2.1 billion, with its median value being $2.2 billion (2023).
  • In the last 5 years, Vertex Pharmaceuticals' Gross Profit soared by 2925.18% in 2021 and then skyrocketed by 252.13% in 2025.
  • Quarter analysis of 5 years shows Vertex Pharmaceuticals' Gross Profit stood at $1.8 billion in 2021, then increased by 10.64% to $2.0 billion in 2022, then increased by 6.45% to $2.1 billion in 2023, then rose by 15.76% to $2.5 billion in 2024, then rose by 9.46% to $2.7 billion in 2025.
  • Its last three reported values are $2.7 billion in Q4 2025, $2.7 billion for Q3 2025, and $2.6 billion during Q2 2025.